Biostimulants vs Biofertilisers: Definitions, Claims, and What to Measure in the Field

The terms biostimulant and biofertiliser are often used side by side, and sometimes used too loosely. That creates confusion for growers, agronomists, distributors and procurement teams who are trying to compare products on a practical basis.

The distinction matters because these products are not meant to do the same job, they are not framed in the same way by guidance, and they should not be judged by the same field measurements. A product that helps a crop cope with drought stress is not making the same promise as one that supplies or mobilises nutrients. If those two ideas are blended together, claims become vague and trial results become hard to interpret.

For commercial agriculture, that is more than a wording issue. It affects product selection, programme design, regulatory status, trial setup and, in the end, gross margins.

Biostimulant definitions in UK and EU guidance

UK HSE guidance gives one of the clearest working definitions. A plant biostimulant is a product that stimulates plant nutrition processes independently of its nutrient content. The key point is not whether the formulation contains some nutrients. The key point is that the intended effect is not direct fertilisation.

Under UK and EU framing, the accepted aims are specific. A biostimulant should be used to improve nutrient use efficiency, support abiotic stress tolerance, improve crop quality traits, or increase the availability of confined nutrients in the soil or rhizosphere.

That means a true biostimulant claim sits around plant processes and plant response.

It does not mean any positive crop effect can simply be labelled a biostimulant effect. If the core value proposition is direct nutrient supply, then the product sits in different territory. If the claim drifts into pest or disease control, regulatory treatment may also change because, as HSE notes, classification depends on both the claims made and the effect produced.

This is why precise wording matters so much. “Supports phosphorus acquisition under low-availability conditions” is a different sort of claim from “supplies phosphorus to the crop”. One is about helping access or use nutrients more effectively. The other is about providing nutrients.

Biofertiliser definitions and nutrient supply roles

Biofertiliser is still a term used with some variation in practice, yet the broad distinction is widely accepted in farmer guidance and technical literature. Biofertilisers are biological materials or organisms used because they supply, mobilise or make nutrients more available to plants. Their value is tied more directly to nutrition.

In simple terms, biostimulants act mainly on plant processes, while biofertilisers act mainly on nutrient supply or nutrient mobilisation.

That difference may sound neat on paper, but field decisions are often less tidy. Some products sit close to the boundary. A microbial formulation may improve root activity, aid phosphorus acquisition and contribute to better crop vigour at the same time. Even then, the commercial question remains straightforward: what is the primary function being claimed, and what evidence supports it?

A useful way to think about it is this. If the product’s value is mainly that it helps the crop use what is already there more efficiently or cope better with stress, it is closer to a biostimulant. If the product’s value is mainly that it fixes, releases, mineralises or supplies nutrients, it is closer to a biofertiliser.

Biostimulants vs biofertilisers: the practical comparison

The easiest way to separate the two categories is to focus on function, claims and proof.

The table is useful, though field reality still demands caution. Some products can affect both plant physiology and nutrient dynamics. That does not remove the need to decide which claim is being tested.

A grower should be able to ask one direct question: What exactly am I paying this product to do?

Claims and regulation for biological crop inputs

Claim discipline is where many commercial discussions go off course. A product may show positive effects in a glasshouse or in a small plot, yet that alone does not justify every possible agronomic claim.

Academic work linked to EU biostimulant claim categories has made this point clearly. Claims should be matched to recognised categories, and results should be reported in empirical terms. Yield matters commercially, even if yield itself is not one of the core regulatory claim categories for a biostimulant. That is a subtle but important distinction.

A product can be sold on improved nutrient use efficiency, yet still needs to show what that meant in practice.

After the claim is defined, evidence should follow the same line. If a product is promoted for abiotic stress tolerance, then the trial must include or clearly document the relevant stress. If a product is promoted for access to confined nutrients, then soil conditions, nutrient status and rhizosphere context need to be described properly.

This is also why it is risky to rely on generic language. Terms like “boosts plant health” or “improves performance” are too broad to be useful unless they are pinned to measurable outcomes. Strong agronomy starts with a narrow claim and a matching trial design.

Field measurements for biostimulants and biofertilisers

The most valuable field data are direct, crop-relevant and linked to the promise being made. Farmer guidance and technical literature both point in the same direction here: do not stop at indirect proxies.

A greener crop canopy or a more vigorous early root system may be interesting, but they are not enough on their own. The decisive measurements are the ones that show what happened in the harvested crop, in nutrient use, or in stress response under real conditions.

Good field work often includes a mix of final outcomes and intermediate measurements:

• yield
• marketable yield
• crop quality
• nutrient uptake
• nutrient use efficiency
• stress symptoms
• harvest timing
• gross margins

Those outputs will not all matter in every crop. Salad leaves, milling wheat, processing tomatoes and protected berries each have different value drivers. Yet the principle stays the same: measure what the buyer, grower or packer actually values.

For biostimulants, the most relevant field measurements often include the following:

• Nutrient use efficiency: yield or quality per unit of nutrient applied, not just tissue nutrient concentration alone
• Abiotic stress tolerance: performance under heat, drought, salinity or cold events compared with untreated controls
• Quality traits: dry matter, colour, size class, sugar content, storage performance or processing quality
• Access to confined nutrients: uptake and output where nutrients are present but not readily available in the rhizosphere

For biofertilisers, the emphasis shifts slightly. Measurements may include nutrient contribution, nutrient mobilisation, plant uptake, reduced need for mineral fertiliser, and the harvested response that follows.

The key is not to rely on a single flattering number. A tissue test, SPAD reading or root image can support the story, but it should not replace the commercial endpoints.

Trial design for biostimulant field validation

Open-field biostimulant results are variable. Recent synthesis work reported an average growth and yield increase of 9.3% across a large combined dataset, yet responses varied significantly by crop and by growth conditions. Controlled nursery plus field systems tended to outperform field-only conditions.

That variability is not a weakness in itself. It is a reminder that context matters.

Biostimulants interact with weather, soil type, crop genetics, baseline fertility, irrigation, previous stress, timing and application method. A result from one site may be useful, but it is not automatically transferable across different geoclimatic conditions.

This is where trial design earns its place. Sound studies should document soil characteristics, crop status and stress conditions, and should use replicated randomised blocks with enough replication to show a reliable treated-versus-untreated difference.

When trials are being planned, a few design features make the evidence much stronger:

• Matched controls: untreated plots and, where relevant, standard programme comparisons
• Replicated randomised blocks: enough repeats to separate treatment effects from field noise
• Clear site characterisation: soil texture, nutrient status, moisture conditions, pH and previous management
• Defined stress context: whether the crop actually experienced the abiotic stress linked to the claim
• Commercial endpoints: harvested yield, quality and margin, not just early visual response

A poorly controlled trial can make a good product look inconsistent. A weak product can also look better than it is if the measurements are selective. That is why rigorous field validation is not a luxury. It is the only way to judge true repeatability.

Why proxies alone are not enough in field agronomy

Proxy measurements have value. They can help explain why a response happened. They can also help technical teams refine timing, dose and placement. Yet proxies should support decisions, not dominate them.

Take root growth as an example. A stronger root system may suggest better nutrient scavenging or improved resilience under water limitation. That is useful information. Even so, if the crop finishes with no meaningful gain in output, quality or nutrient efficiency, the agronomic value remains unproven.

The same applies to leaf colour, enzyme activity, microbial counts or biochemical markers. These can all be informative, but they are not the end point that matters to a grower balancing input cost against return.

That is especially relevant for premium biological inputs. When pricing reflects innovation, evidence must also reflect on-farm reality.

Choosing between biostimulants and biofertilisers in crop programmes

The choice should start with the problem, not the product category. If the main issue is nutrient supply, nutrient fixation or nutrient mobilisation, a biofertiliser-oriented approach is usually the clearer fit. If the main issue is nutrient efficiency, quality response or resilience under abiotic stress, a biostimulant-oriented approach may be more suitable.

That sounds simple, yet it becomes powerful when linked to programme planning.

A practical decision framework often looks like this:

1. Define the limiting factor in the crop.
2. Match the product claim to that limiting factor.
3. Check whether local or crop-relevant field data support the claim.
4. Measure success using direct commercial outcomes.

This approach helps avoid a common mistake: using a biostimulant as though it were a substitute for base nutrition, or using a biofertiliser as though it were primarily a stress-management tool. Biological products can be highly effective, but they still need a defined job within the programme.

For distributors and advisers, this clarity also improves communication with growers. It becomes easier to explain expected performance, realistic timing windows and the right way to assess return on investment.

For growers, the standard is refreshingly practical. Ask what the product is meant to do, how that claim is framed, and what was measured in the field to prove it. If the answer centres on direct outcomes in the target crop under relevant conditions, confidence rises. If the answer leans on proxies, broad language or unrelated trial contexts, caution is sensible.

That mindset gives biological inputs the fairest possible test, and it gives the farm business a much better basis for deciding where each product belongs.